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Sinary Tyrosine proten kia (TPK) has been assocated with the cytoplasmi domain ofgrowth
factor receptors as wel as oncoproteins. Enzymatic activation appears to be a major initial event in these
signal transduction pathways. In this study, TPK was determined in the cytosols of 249 nod-positive primary
breast tumours. Enzyme activity was measured [IPJATP and poly(glutamic acid-tyrosine) (4:1) as an
artfifial substrate. Leves of TPK varied from 0 to 35.9pmol ATP min- mg' protein (median 11.4). No
correlation was found with tumour size or number of positive lymph nodes. In contrast, kveis of TPK were
negatively associated with age (P = 0.01) and menopausal status (P<0.05) of the patients. Higher concentra-
tons ofTPK were in addition found in tumours negative for oestradiol (P<0.01) and progerone (P<0.05)
receptors. Fmally, a positive correlation was found between TPK and urokinase pa activator (UPA)
(P<0.05). Patients whose tumours contained high kves of TPK had reduced disease-free (P= 0.01) and
overall survival (P<0.05). In Cox mulftivariate analysis, ing patient's age, menopausal status, tumour
size, number of positive lymph nodes, steroid receptors and UPA, TPK retained its independent prognostic
importance.
The mechanisms by which peptide growth factors regulate
cell differentiation, tumour growth and invasion are complex.
However, the binding of several growth factors to their mem-
brane receptors results in activation of an intrinsic tyrosine-
specific protein kinase (TPK), which, is a major initial event
in these signal transduction pathways PJiUrich & Schlessinger,
1990; Fisher et al., 1991; Wl1ks, 1993). TPK activity therefore
represents an excellent biological target for the development
of new cancer drugs (Dvir et al., 1991; Ennis et al., 1991).
New therapeutic strategies diected against growth factors
might thus include tyrosine kinase inhibitors to interfere with
signalling transduction cascades after growth factor is bound
to its receptor (Harris et al., 1992).
In breast cancer, nearly all the known sources for TPK
activity, including epidermal growth factor (EGF) receptors
(EGFR) (Sainsbury et al., 1987), insulin-like growth factor
type 1 (IGF-1) receptors (IGF-lR) (Foekens et al., 1989),
HER-2 (Slamon et al., 1987) and c-src gene products
(Ottenhoff-Kalff et al., 1992) are bound to the plasma mem-
brane (Cantley et al., 1991; Fisher et al., 1991). Inreased
TPK activity has, however, been described in both membrane
and cytosol fractions (Hennipman et al., 1989; Durocher &
Chevaler, 1990; Lower et al., 1993). The signifi of
cytosolic TPK expression remains to be clarified.
The initial report of Sainsbury et al. (1987) suggested that
amplcation of EGFR was a poor prognostic factor in
node-negative breast cancer patients. However, the role of
EGFR as a prognostic indicator for patients with breast
cancer is currently a matter of extensive debate (Klijn et al.,
1992; Spyratos et al., 1994). There is aLso little agreement on
the prognostic value of-HER-2 (SLamon et al., 1987; Berns et
al., 1992) and IGF-IR (Foekens et al., 1989; Peyrat et al.,
1990). In contrast to selective detection of a single growth
factor receptor or oncoprotein, overall measurement of TPK
actmity expression might reflect integrated tumour aggres-
siveness (Dougall et al., 1993). TPK activity might thus
provide powerful prognostic information regarding women
with breast cancer.
In this study, cytosolc TPK activity was measured m 249
patients with node-positive primary breast tumours, a subset
of patients which has been previously evaluated for steroid
receptors and urokinase-type plainogen activator (UPA)
(Foekens et al., 1992). The association of TPK levels with
classicl prgnostic factors, disease-free and overall survival,
was studied to determine its possible clinical usefulness, and
the relative importance of TPK was by Cox multi-
variate analysis.
Materal and -Ptho
Patients and tisses
This study was performed on a group of 249 node-positive
patients with operable primary breast cancer and without
signs of distant meastasis at surgery. Selection of patients
was made on the basis of the availability of tumour cytosol
of the 394 node-positive patients included in the study
reported previously (Foekens et al., 1992). All patients under-
went primary surgery in or were referred to the Daniel den
Hoed Cancer Center for (adjuvant) radiotherapy of the
primary tumour between 1978 and 1988. Table I shows the
characteristics of the patients with respect to age, meno-
pausal status, tumour size, number of positive lymph nodes,
differentiation of the tumour at the time of surgery and
post-operative treatment Patients were clasfied as pen-
menopausal if they had irregular and kss frequent men-
struations (less than once every 3 months) and their last
menstruation was not longer than 1 year before inclusion in
the study. For patients who underwent axillary surgery, his-
tological emination was used to confirm the number of
lymph nodes with tumour involnement. The ten patients who
did not undergo axillary surgery were all clasfied as having
more than three positive nodes on the basis ofaxillary lymph
node mass and confirmation of tumour involvement by
biopsy. Nearly all patients ultimately reived some form of
irradiation either on the breast/thoracic wall and/or on one
or more lymph node areas. Patients with medially or cen-
trally located T1/I2 tumours or T3/T4 tumours were
iradiated on the parasternal lymph nodes. Premenopausal
women generally recived adjuvant chemotherapy (cyclo-
phosphamide, methotrexate, 5-fluorouracil) (74/85). Post-
menopausal women older than 55 years generally received no
adjuvant therapy (133/164).
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Table I Characterstics ofpatints, tumours and treatments
Characteristics Frequency
Patients
Total number
Age, mean (range)(years)
Menopausal status
Premenopausal
Postmenopausal
Perimenopausal
Twnours
Size
TI (<2cm)
T2 (2-5 cm)
T3 (>S5 cm)
T4
Number ofpositive nodes
1-3
>3
Differentiation grade
Well
Moderately
Poorly
249
57.9 (27-90)
75
158
11
61
127
33
25
133
116
2
50
134
Treatment
Surgery ofprimary tumour
Modified mastectomy 180
Breast-conserving lumpectomy 65
Biopsy only 4
Surgery of the axilla
Dissection 239
None 10
Radiotherapy
Breast or thoracic wall 143
Axilla 180
Other lymph node areas 192
Systemic adjuvant therapy
Chemotherapy (CMF) 94
Hormonal therapy 20
Owing to a few missing patients characteristics, the numbers of
patients do not always add up to 249.
Follow-up
All patients were routiely examine every 3-6 months dur-
ing the first 5 years and once a year thereafter (median
follow-up 49 months; range 23-128 months). Of the 249
patients included in this study, 93 have died, 80 after a
previous relapse. In 127 patients recurrence of disease was
deteted during follow-up, and these patients count as
failures in the analysis of disease-free survival.
Assay ofsteroid receptors, UPA and TPK
Processing and pathological examination of tumours was
performed as described previously (Foekens et al., 1989).
Tumour tissue was stored in liquid nitrogen. Cytosols were
prepared in 10mm dipotassium hydrogen phosphate buffer
[containing 1.5 mM dipotassium chloride EDTA, 3 mM
sodium azide, 10mM monothioglycerol and 10% (v/v) gly-
cerol, pH 7.4]. The values of the cytosolic parameters were
not adjusted for histologically assessed perntage of tumour
content.
For routine binding assays ofcytosolic oestradiol receptors
(ER) and progesterone receptors (PR), the dextran-coated
charcoal method with multiple-point Scatchard analysis was
used according to the procedures as recommended by the
European Organization for Research and Treatment of
Cancer (EORTC, 1980). The cut-off point used for both was
10fmol mg-' protein. The same cytosols were used for the
assessment of UPA and TPK.
UPA antigen was measured by enzyme-linked immunosor-
bent assay, as described previously in detail (Foekens et al.,
1992), using reagents of a kit which is now commerially
available (uPA Elisa kit A894, American Diagnostica, Green-
wich, USA).
TPK enzyme activity was determined as previously des-
cribed (Bolla et al., 1993), using [32P1ATP as the phosphate
donor and poly(glutamic acid-tyrosine) (4:1) as an artificial
substrate. Briefly, an aliquot of the cytosol (20pg of protein)
was incubated in the presence of 5 mM [-32PJATP (specific
activity 3,000 Cimmol'1), 240pgml-l artificial substrate
poly-Glu-Tyr (4:1) (Sigma) in 20 mM HEPES buffer,
pH 7.5, conting 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
60jM sodium vanadate, 5 mM sodium fluoride and 8.5 mM
manganese chloride. The phosphorylation reaction was run
at 20-C for 20min and stopped upon addition of 1 ml of
10% trichloracetic acid. The mixture was passed through
GF/C Whatman filters, which were counted for their radioac-
tivity content, following 2 x 10 ml washes with 10% trichlor-
acetic acid. TPK activity was corrected for endogenous
phosphorylation measured in the absnce of substrate. TPK
levels are expressed in pmol ATPmin-' mg-' protein.
Statistics
Linear regression analysis was used to study the correlations
between TPK and patients and tumour characteristics. In
univariate regression analysis, a highly significant trend
(P= 0.005) between the log of TPK concentration and the
rate of relapse was observed. Subsequently, isotonic regres-
sion analysis (Barlow et al., 1972) was applied to check
whether a dichotomy or a more or less continuous trend was
present. For UPA, a cut-off value of 1.15 ngmg'1 protein, as
previously determined in a larger breast cancer population
was used (Foekens et al., 1992). Disease-free and overall
survival probabilites were calculated by the method of Kap-
lan-Meier. The likelihood ratio test in the univariate Cox
regression model was used to test for differences and trend.
The Cox proportional hazard model was also applied for
multivariate analyses. The results of the Cox regression
analysis are smmarised by the relative relapse and relative
death rates. For the Cox regression analyses, the complete
follow-up data were used. The survival curves were limited to
5 years.
Res
Association between TPKandpatient and twnour
characteristics
Cytosolic TPK activity varied from 0 to 35.9 pmol ATP
min-1mg-I proten (median 11.4; mean +s.d. 12.1 ± 6.8).
No correlation was found with tumour size, number of
positive lymph nodes or differentiation grade (Table II). TPK
levels were negatively associated with age and menopausal
status of the patients. In addition, higher concentrations of
TPK were found in ER-negative and PR-negative tumours as
compared with receptor-positive tumours. Finally, a positive
correlation was found between TPK and UPA.
Associations ofTPKand otherfactors with (disease-free)
survival
Table Im shows the factors statistically associated with
disease-free and overall survival. Age and menopausal status
showed no association. Larger tumour size was associated
with a reduced disease-free survival. The number of positive
lymph nodes was positively associated with both a shorter
diseasfree and overall survival. ER-PR positivity was
associated with a favourable prognosis, whereas high levels
of UPA were associated with reduced disease-free and overall
survival.
In a test for trend in Cox univariate analysis, logarith-
mically transformed TPK levels were negatively associated
with disease-free survival (P=0.005). Isotonic regrssion
analysis showed a more or less continuous association
between the relapse rate and the value of TPK. The median
value was therefore arbitrarily chosen as cut-off point to
discriminate high- and low-TPK tumours to enable a
graphical display with survival curves. Kaplan-Meier curves3S6 S. ROMAIN et al.
Table H Relation between TPK and patient and tumour character-
istics
>11.4
Characteristics n Mean s.d. (%)- P-value
Total 249 12.1 6.8 50.0
Age (years)
.1 50 80 13.7 7.8 57.5
50-65 93 11.5 6.4 47.3 0.01
>65 76 11.2 5.9 44.7
Post-menopausal
No 85 13.5 7.8 56.5 <0.05
Yes 164 11.4 6.2 46.3
Tumour size
Ti 61 12.1 6.9 45.9
T2 127 12.6 6.9 52.8 NS
T3 33 10.3 6.9 39.4
T4 25 11.9 6.2 56.0
No. ofpositive nodes
1-3 133 12.0 6.4 51.1 NS
>3 116 12.2 7.3 48.3
Grade
Wellb 2 6.2 5.4 0.0
Moderately 50 12.2 5.8 50.0 NS
Poorly 134 12.7 7.3 54.5
ER status
- 61 14.4 8.4 62.3 <0.01
+ 188 11.4 6.1 45.7
PR status
- 84 13.4 7.7 57.1 <0.05
+ 156 11.6 6.2 46.1
UPA status
- 162 11.4 6.8 46.3 <0.05
+ 87 13.4 6.7 56.3
s.d., standard deviation; P-value by inear
aMedian value in pmol ATPmin' mg-' protein.
regression analysis.
.bOnlyn =2.
Table m Actuanial probabities of 5 year disease-free and overaH
survival of patients, as stratified by patient and tumour character-
istics
DFS OS
% pP P
Age (years)
<50 54 68
50-65 40 NS 62 NS
>65 38 49
Post-menopausal
No 55 NS 68 NS
Yes 38 55
Tumour size
Ti 59 73
T2 49 <0.001 58 NS
T3 24 58
T4 0 37
No. of positive nodes
1-3 53 <0.0001 70 <0.0001
>3 32 45
Grade
Ia 100 100
II 46 NS 71 NS
III 43 56
ER-PR status
+/+ 47 <0.05 69 0.001
Othersb 38 42
UPA status
51 <0.0001 64 <0.05
+ 29 50
TPK status
Low 50 0.01 65 <0.05
High 37 53
DFS, disease-free survival; OS, overall survival; P, P-vahie; NS, not
significant. aonly n = 2. bIThe combined group of the three other
phenotypes with one or both receptors negative.
for actuarial disease-free (Figure la) and overall survival
(Figure lb) show the increased hazard rates of our patients
with TPK-positive primary tumours.
Cox multivariate analysis ofTPK status
The independent predictive value of TPK on the rate of
relapse and death was with Cox multivariate
analysis including various clinical and histological parameters
(age, menopausal status, tumour size, number of positive
lymph nodes), ER-PR status and UPA (Table IV). Two
hundred and thirty-seven patients with complete data were
analysed. For disease-free survival, the dominant factors
selected in the standar model were tumour size and the
number of positive lymph nodes. For overall survival,
relevant variables were the number of positive lymph nodes,
ER-PR status and tumour size. For both analyses, UPA
status (+ vs -) and TPK status (high vs low) significantly
added to the model with relative relapse rates of 2.18 and
1.74 and relative death rates of 1.71 and 1.58, as shown by
Kaplan-Meier curves for disease-free (Figure 2a) and overall
survival (Figure 2b). Addition of adjuvant chemotherapy as
an indicator variable to the multivariate models did not affect
the estimates of the regression coefficients of the cytosolic
parameters and was therefore not included in the models
presented in Table IV.
Several growth factor receptors and oncoproteins, including
EGFR (Sainsbury et al., 1987), IGF-1R (Foekens et al.,
1989; Peyrat et al., 1990) and HER-2 (Slamon et al., 1987),
have been reported in breast tumours. At present, however,
there is little agreement on some clinical relationship and
their prognostic value (Berns et al., 1992; Klijn et al., 1992).
Lack of a standardised assay is probably one of the most
important reasons for the variability observed (Koenders et
al., 1992; Spyratos et al., 1994). In addition, a single growth
factor receptor or oncoprotein probably cannot reliably
account for all the cellular signals that occur during tumour
growth, invasion and metastasis (Dougall et al., 1993). TPK
activity has been associated with the cytoplasmic domain of
many growth factor receptors as well as oncogene products
(Cantley et al., 1991; Fisher et al., 1991). TPK measurement
might thus result in more accurate prediction of patient
clinical behaviour than selective measurement of these pro-
teins.
In this study, cytosolic TPK activity was assessed in
tumours from 249 node-positive primary breast cancer
patients. Although TPK has been associated with membrane-
bound protiens (Cantley et al., 1991; Fisher et al., 1991),
measurement of TPK activity in cytosol better separates
normal breast tissues, benign breast diseases and breast
cancers than membrane-bound TPK activity (Hennipman et
al., 1989; Lower et al., 1993). Moreover, assay of cytosols
appears to be more appropriate for rouine use. Measure-
ments were thus performed in cytosols routinely prepared for
steroid receptor measurement. We determined TPK enzyme
activity using [V2PATP and a polypeptide artificial substrate
(Bolla et al., 1993). An enzyme-linked immunosorbent assay
(ELISA) has been recently described for TPK measurement
(Schraag et al., 1993). At present, little is known about the
correlation between the activity data obtained with enzyme
activity assay and antigen measurement by ELISA.
The levels of TPK in our study are in agreement with
previously published data using the same assay (Bolla et al.,
1993). However, we report a strong negative correlation
between TPK and ER levels, a relationship not found
previously in pilot studies with few patients (Hennipman etTYROSINE PROTEIN KINASE AND BREAST CANCER 317
TaMie IV Cox multivariate analysis ofclinicaL, histological and biological factors
Disease-free survival Overall survival
Relaive relapse rate Relative death rate
(95% conidne lmits) P (95% conidne linits) P
Age and menopausal statusa NS NS
Age preMenopaUSalb 0.72 (0.46-1.15) 0.71 (0.40-1.24)
Age post-menopausalb 0.90 (0.69-1.17) 1.24 (0.94-1.65)
Menopausal statuse 2.26 (1.15-4.41) 1.51 (0.65-3.48)
Tumour sized 1.54 (1.25-1.88) <0.0001 1.27 (1.00-1.61) <0.05
No. of positive nodest 1.85 (1.27-2.69) 0.001 1.93 (1.26-2.97) <0.01
ER-PR statusf 0.85 (0.58-1.24) NS 0.57 (0.37-0.86) 0.01
UPA status5 2.18 (1.50-3.16) <0.0001 1.71 (1.12-2.63) 0.01
TPK statush 1.74 (1.18-2.56) 0.005 1.58 (1.02-2.46) <0.05
P, P-value. 'Age and menopausal status combined. bAge in decades tested separtely for premenopausal
(= pre- + perimenopausal) and post-menopausal patients. 'Post-menopausal vs pre-/perimenopausal. 'Scored as
I = Ti to 4= T4. '>3 vs 1-3. fER and PRpositivecompared with the combined group ofthe three otherphenotypes
withoneorbothreceptorsnegative.5UPApositiveascomparedwithUPAnegative.hTPKhighascomparedwithTPK
low.
a
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Fmgwe 1 Actuarial diease-free survival a, and overall survival b,
curves stratified by TPK status. The cut-off vahle for TPK was
11.4 pmol ATP min-'mg-' protein- Numbers represent the
number of failures out of the total number of patients in each
group.
al., 1989; Durocher & Chevalier, 1990; Bolla et al., 1993;
Lower et al., 1993). This relationship is similar to that des-
cribed for EGFR (Foekens et al., 1989; Klijn et al., 1992)
and HER-2 (Berns et al., 1992). However, TPK activity has
been associated with many growth factor receptors and
oncoproteins. Moreover, at least 70% of the TPK activity in
breast cancer cytosols originates from the presence of the
c-src oncogene product (Ottenhoff-Kalif et al., 1992), and the
contribution of EGFR to TPK activity seems to be low
(Durocher & Chevalier, 1990). In this study, high TPK levels
were negatively associated with age and menopausal hor-
Fugwe 2 Actuarial disease-free surval a, and overall survival b,
curves stratfied by both UPA and TPK status. The cut-off vahle
for UPA was 1.15 ngmg-' protein. The cut-off value for TPK
was 11.4 pmol ATPmin 'mg' protein. Numbers represent the
number of failures out of the total number of patients in each
group.
monal status of the patients. Finally, a positive correlation
was found between TPK and UPA, which suggests that
protease expression may be regulated by growth factors of
the TPK family (Laiho & Keski-ga, 1989; Neidbala & Sar-
torelli, 1989).
High levels of TPK were associated with an increased risk
of relapse and death. These data concerning disease-free
survival are in agreement with the few previously published
pilot studies, which included 18 patients (Hennipman et al.,
1989), 86 patients (Lower & Williams, 1992) and 40 node-
negative and 40 node-positive patients (Bolla et al., 1993).
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TPK retained its prognostic importance in Cox multivariate
analysis, including classical clinical and histological factors,
steroid receptors and UPA. However, the protease expres-
sion, which has been related mainly to invasion and meta-
stasis, appeared as a stronger prognostic factor. ER and PR
were stronger predictors of overall survival than of disease-
free survival, probably because of the better response to
palliative hormonotherapy of ER-positive patients (Nomura
et al., 1992). In contrast, disease-free survival and overall
survival were equally affected by TPK. The relationship
between TPK and sensitivity to adjuvant therapy needs to be
clarified. In this study, it could not accurately be assessed
because adjuvant therapy was predominantly given to
premenopausal patients. Interestingly, however, addition of
adjuvant therapy to the multivariate model did not affect the
estimates of the cytosolic parameters, including that of TPK.
Assessment of TPK could be helpful for the identification
of patients at high risk of recurrence, and thus for the
selection of patients for adjuvant therapy. However, the
prognostic value of TPK must be confirmed in prospective
studies. Measurement of TPK activity might in addition
become important in predicting response to TPK inhibitors,
of which many are likely to be tested in clinical trials in the
near future.
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